Novai is a British biotechnology start-up, developing and commercialising DARC (Detection of Apoptosing Retinal Cells), which is approved as an exploratory biomarker by FDA, MHRA and TGA for use in Age-related Macular Degeneration (AMD), Glaucoma and other clinical studies.
DARC combines an innovative patented biologic with a state-of-the-art AI algorithm and uses standard imaging equipment to identify cellular level disease activity.
Novai is built on a vision to preserve sight through early detection and treatment of ophthalmic disease using advanced technologies and bringing value to its stakeholders in the process.
Novai proposes to achieve this vision in 3 ways:
- Supporting pharma and biotech drug development sales through value added biomarker based on DARC technology by de-risking and accelerating clinical trials
- Bringing DARC to market as a diagnostic for Glaucoma detection and therapy prognosis, as a first indication. The diagnostic market focus will be in the US and EU/UK as initial target market (with likely licensing opportunities across other global markets)
- Opportunities for novel expansions of the DARC biologic molecule as a targeted drug delivery vehicle or theranostic which can overcome biological barriers known to impede drug delivery to eye and brain